T-DM1 in Early HER2+/HR+ Breast Cancer Offers Good Response Rates

T-DM1 administered for 12 weeks with or without endocrine therapy yields good rates of pathologic complete response in women with HER2-positive/hormone receptor –positive breast cancer, according to a new randomized trial.

Source: CancerNetwork - July 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news